|
|
|
|
|
|
Sponsored by: |
International Extranodal Lymphoma Study Group (IELSG) |
Information provided by: | International Extranodal Lymphoma Study Group (IELSG) |
ClinicalTrials.gov Identifier: | NCT00210353 |
Aim of the study is to assess the therapeutic activity and safety of the combination of Chlorambucil and Rituximab in MALT lymphomas and to determine whether the addition of Rituximab to Chlorambucil will improve the outcome of MALT lymphoma in comparison to treatment with Chlorambucil alone
Condition | Intervention | Phase |
Lymphoma, Mucosa-Associated Lymphoid Tissue |
Drug: rituximab (drug) Drug: chlorambucil (drug) |
Phase III |
MedlinePlus related topics: | Lymphoma |
ChemIDplus related topics: | Rituximab Chlorambucil |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab in Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) |
Estimated Enrollment: | 250 |
Study Start Date: | January 2003 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contact: Cristina Morinini | +41 91 8119040 | ielsg@ticino.com |
Switzerland | |||||
Oncology Institute of Southern Switzerland - Ospedale San Giovanni | Recruiting | ||||
Bellinzona, Switzerland, 6500 | |||||
Contact: Cristina Morinini +41 91 8119040 ielsg@ticino.com |
International Extranodal Lymphoma Study Group (IELSG) |
Study Chair: | Emanuele Zucca, MD | International Extranodal Lymphoma Study Group/Oncology Institute of Southern Switzerland. Bellinzona |
Study Chair: | Emilio Montserrat, MD | Clinic Hospital Universitari, Hematology. Barcelona |
Study Chair: | Catherine Thieblemont, MD | Centre Hospitalier Lyon Sud, Hematology. Lyon |
Study Chair: | Giovanni Martinelli, MD | Hemato-oncology. European Oncology Institute. Milan |
Study Chair: | Peter Johnson, MD | Oncology Unit. Southampton General Hospital. Southampton |
Study Chair: | Maurizio Martelli, MD | Hematology. Università La Sapienza. Roma |
Click here for more information about this study 
  |
Study ID Numbers: | IELSG19 |
First Received: | September 13, 2005 |
Last Updated: | December 13, 2005 |
ClinicalTrials.gov Identifier: | NCT00210353 |
Health Authority: | Switzerland: Swissmedic |
|
|
|
|